Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats

Youxue Wang, Satoru Naruse, Motoji Kitagawa, Hiroshi Ishiguro, Yasuyuki Nakae, Toshiyuki Yoshikawa, Tetsuo Hayakawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The effects of a new benzodiazepine-derivative, cholecystokinin receptor antagonist, TS-941, on experimental acute pancreatitis were studied in rats. Hemorrhagic pancreatitis was induced by an infusion of a mixture of trypsin and taurocholate into the pancreatic duct. Edematous pancreatitis was induced by intraperitoneal injection of 40 μg/kg body weight of cerulein at 0 and 1 h after the start of the experiment. TS-941 (3 mg/kg) was injected subcutaneously immediately and 3 h after the induction of pancreatitis. In trypsin-taurocholate-induced pancreatitis, TS-941, with or without the synthetic trypsin inhibitor ONO-3403, had no beneficial effects on the survival rate, pancreatic wet weight, and serum pancreatic enzymes. In cerulein-induced pancreatitis, the treatment with TS-941 significantly reduced the increases of pancreatic wet weight and serum amylase and lipase. Plasma trypsinogen activation peptide (TAP) significantly rose 1 h after the first injection of cerulein. TS-941 inhibited the liberation of TAP in cerulein-induced pancreatitis. These results show that TS-941 is effective for prevention of cerulein-induced edematous pancreatitis. ONO-3403 has beneficial effects on trypsin-taurocholate-induced hemorrhagic pancreatitis, but the combination of TS-941 and ONO-3403 has no additive effect.

Original languageEnglish (US)
Pages (from-to)289-294
Number of pages6
JournalPancreas
Volume17
Issue number3
StatePublished - Oct 1998

Fingerprint

Cholecystokinin
Pancreatitis
Ceruletide
trypsinogen activation peptide
Taurocholic Acid
Trypsin
Cholecystokinin Receptors
TS 941
Weights and Measures
Trypsin Inhibitors
Pancreatic Ducts
Amylases
Intraperitoneal Injections
Serum
Lipase
Benzodiazepines
Body Weight
Injections
Enzymes

Keywords

  • α macroglobulin trypsin complex
  • Cholecystokinin receptor antagonist
  • Experimental pancreatitis
  • Trypsinogen activation peptide (TAP)

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology

Cite this

Wang, Y., Naruse, S., Kitagawa, M., Ishiguro, H., Nakae, Y., Yoshikawa, T., & Hayakawa, T. (1998). Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats. Pancreas, 17(3), 289-294.

Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats. / Wang, Youxue; Naruse, Satoru; Kitagawa, Motoji; Ishiguro, Hiroshi; Nakae, Yasuyuki; Yoshikawa, Toshiyuki; Hayakawa, Tetsuo.

In: Pancreas, Vol. 17, No. 3, 10.1998, p. 289-294.

Research output: Contribution to journalArticle

Wang, Y, Naruse, S, Kitagawa, M, Ishiguro, H, Nakae, Y, Yoshikawa, T & Hayakawa, T 1998, 'Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats', Pancreas, vol. 17, no. 3, pp. 289-294.
Wang Y, Naruse S, Kitagawa M, Ishiguro H, Nakae Y, Yoshikawa T et al. Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats. Pancreas. 1998 Oct;17(3):289-294.
Wang, Youxue ; Naruse, Satoru ; Kitagawa, Motoji ; Ishiguro, Hiroshi ; Nakae, Yasuyuki ; Yoshikawa, Toshiyuki ; Hayakawa, Tetsuo. / Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats. In: Pancreas. 1998 ; Vol. 17, No. 3. pp. 289-294.
@article{70aeb53a8760407eb1abd85658d63978,
title = "Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats",
abstract = "The effects of a new benzodiazepine-derivative, cholecystokinin receptor antagonist, TS-941, on experimental acute pancreatitis were studied in rats. Hemorrhagic pancreatitis was induced by an infusion of a mixture of trypsin and taurocholate into the pancreatic duct. Edematous pancreatitis was induced by intraperitoneal injection of 40 μg/kg body weight of cerulein at 0 and 1 h after the start of the experiment. TS-941 (3 mg/kg) was injected subcutaneously immediately and 3 h after the induction of pancreatitis. In trypsin-taurocholate-induced pancreatitis, TS-941, with or without the synthetic trypsin inhibitor ONO-3403, had no beneficial effects on the survival rate, pancreatic wet weight, and serum pancreatic enzymes. In cerulein-induced pancreatitis, the treatment with TS-941 significantly reduced the increases of pancreatic wet weight and serum amylase and lipase. Plasma trypsinogen activation peptide (TAP) significantly rose 1 h after the first injection of cerulein. TS-941 inhibited the liberation of TAP in cerulein-induced pancreatitis. These results show that TS-941 is effective for prevention of cerulein-induced edematous pancreatitis. ONO-3403 has beneficial effects on trypsin-taurocholate-induced hemorrhagic pancreatitis, but the combination of TS-941 and ONO-3403 has no additive effect.",
keywords = "α macroglobulin trypsin complex, Cholecystokinin receptor antagonist, Experimental pancreatitis, Trypsinogen activation peptide (TAP)",
author = "Youxue Wang and Satoru Naruse and Motoji Kitagawa and Hiroshi Ishiguro and Yasuyuki Nakae and Toshiyuki Yoshikawa and Tetsuo Hayakawa",
year = "1998",
month = "10",
language = "English (US)",
volume = "17",
pages = "289--294",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effects of a new cholecystokinin antagonist, TS-941, on experimental acute pancreatitis in rats

AU - Wang, Youxue

AU - Naruse, Satoru

AU - Kitagawa, Motoji

AU - Ishiguro, Hiroshi

AU - Nakae, Yasuyuki

AU - Yoshikawa, Toshiyuki

AU - Hayakawa, Tetsuo

PY - 1998/10

Y1 - 1998/10

N2 - The effects of a new benzodiazepine-derivative, cholecystokinin receptor antagonist, TS-941, on experimental acute pancreatitis were studied in rats. Hemorrhagic pancreatitis was induced by an infusion of a mixture of trypsin and taurocholate into the pancreatic duct. Edematous pancreatitis was induced by intraperitoneal injection of 40 μg/kg body weight of cerulein at 0 and 1 h after the start of the experiment. TS-941 (3 mg/kg) was injected subcutaneously immediately and 3 h after the induction of pancreatitis. In trypsin-taurocholate-induced pancreatitis, TS-941, with or without the synthetic trypsin inhibitor ONO-3403, had no beneficial effects on the survival rate, pancreatic wet weight, and serum pancreatic enzymes. In cerulein-induced pancreatitis, the treatment with TS-941 significantly reduced the increases of pancreatic wet weight and serum amylase and lipase. Plasma trypsinogen activation peptide (TAP) significantly rose 1 h after the first injection of cerulein. TS-941 inhibited the liberation of TAP in cerulein-induced pancreatitis. These results show that TS-941 is effective for prevention of cerulein-induced edematous pancreatitis. ONO-3403 has beneficial effects on trypsin-taurocholate-induced hemorrhagic pancreatitis, but the combination of TS-941 and ONO-3403 has no additive effect.

AB - The effects of a new benzodiazepine-derivative, cholecystokinin receptor antagonist, TS-941, on experimental acute pancreatitis were studied in rats. Hemorrhagic pancreatitis was induced by an infusion of a mixture of trypsin and taurocholate into the pancreatic duct. Edematous pancreatitis was induced by intraperitoneal injection of 40 μg/kg body weight of cerulein at 0 and 1 h after the start of the experiment. TS-941 (3 mg/kg) was injected subcutaneously immediately and 3 h after the induction of pancreatitis. In trypsin-taurocholate-induced pancreatitis, TS-941, with or without the synthetic trypsin inhibitor ONO-3403, had no beneficial effects on the survival rate, pancreatic wet weight, and serum pancreatic enzymes. In cerulein-induced pancreatitis, the treatment with TS-941 significantly reduced the increases of pancreatic wet weight and serum amylase and lipase. Plasma trypsinogen activation peptide (TAP) significantly rose 1 h after the first injection of cerulein. TS-941 inhibited the liberation of TAP in cerulein-induced pancreatitis. These results show that TS-941 is effective for prevention of cerulein-induced edematous pancreatitis. ONO-3403 has beneficial effects on trypsin-taurocholate-induced hemorrhagic pancreatitis, but the combination of TS-941 and ONO-3403 has no additive effect.

KW - α macroglobulin trypsin complex

KW - Cholecystokinin receptor antagonist

KW - Experimental pancreatitis

KW - Trypsinogen activation peptide (TAP)

UR - http://www.scopus.com/inward/record.url?scp=0031695221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031695221&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 289

EP - 294

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 3

ER -